Annexon (ANNX) vs Candel Therapeutics (CADL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Candel Therapeutics (CADL) has outperformed Annexon (ANNX) over the past year, gaining 53.3% versus a gain of 27.0%. Over five years, CADL leads with a -1.7% price change compared with -81.8% for ANNX. Annexon is the larger company by market cap ($758.3 million vs $739.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANNX | CADL |
|---|---|---|
| Share price | $4.00 | $9.66 |
| Market cap | $758.32M | $739.17M |
| 1-day change | -0.25% | -1.63% |
| YTD return | -20.32% | +70.97% |
| 1-year return | +26.98% | +53.33% |
| 5-year return | -81.82% | -1.73% |
| EPS (TTM) | $-1.13 | $-1.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.18 | $14.00 |
| 52-week low | $2.54 | $4.35 |
| Distance from 52-week high | -44.29% | -31.00% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +285.75% | +125.16% |
| Average volume | 3.08M | 1.21M |
| Shares outstanding | 189.58M | 76.52M |
| Employees | 92 | 55 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CADL has outperformed ANNX by 26.3 percentage points over the past year.
About Annexon
ANNX stock →Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Candel Therapeutics
CADL stock →Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 55 employees
ANNX vs CADL FAQ
Which is bigger, Annexon or Candel Therapeutics?
Annexon (ANNX) is larger, with a market capitalization of $758.32M compared with $739.17M for Candel Therapeutics (CADL).
Which stock has performed better over the past year, ANNX or CADL?
CADL returned +53.33% over the past 12 months, compared with +26.98% for ANNX (price return, excluding dividends). Past performance does not predict future results.
Are Annexon and Candel Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Annexon and Biotechnology: Biological Products (No Diagnostic Substances) for Candel Therapeutics.